Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX versus BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX versus BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN.
ANAPROX vs BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
250-500 mg orally twice daily; maximum 1.5 g/day; for extended-release: 375-750 mg orally twice daily
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life 12-17 hours; prolonged in elderly (up to 20 hours) and in renal impairment.
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
Renal excretion of metabolites (95%) and unchanged drug (<5%); biliary/fecal elimination minor (<5%).
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and pH-dependent: alkaline urine increases clearance.
Category C
Category D/X
NSAID
NSAID / Antiplatelet